Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos; Michèle Cavo; Joan Bladé; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lúcio; Zsolt Nagy; Luděk Pour; Mark Cook; Sebastian Grosicki; Andre H Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung‐Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Maria Krevvata; Ying Chen; Jianping Wang; Anupa Kudva; Jon Ukropec; Susan Wróblewski; Ming Qi; Rachel Kobos; Jesús F. San Miguel

doi:10.1016/s0140-6736(19)32956-3

Related publications

Article2021

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

María‐Victoria Mateos, Meletios A Dimopoulos, Michèle Cavo, Kenshi Suzuki, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Shinsuke Iida, Joan Bladé, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Anupa Kudva, Ming Qi, Jesús F. San Miguel

Article2007

MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma.

Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Meletios A Dimopoulos, Martin Kropff, Martina Petrucci, Olga Samoilova, Anna Dmoszyńska, Abdulkadyrov Km, Rik Schots, Bin Jiang, Antonio Palumbo, María‐Victoria Mateos, K. Liu, Andrew Cakana, H. Van de Velde, Paul G. Richardson

Article2017

Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)

Thierry Façon, Jae Hoon Lee, Philippe Moreau, Rubén Niesvizky, Meletios A Dimopoulos, Roman Hájek, Muhtarjan Osman, Sanjay Aggarwal, Zandra Klippel, Jesús F. San Miguel

Article2008

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Špıčka, Maria Teresa Petrucci, Antonio Palumbo, Olga Samoilova, Anna Dmoszyńska, Abdulkadyrov Km, Rik Schots, Bin Jiang, María‐Victoria Mateos, Kenneth C. Anderson, Dixie‐Lee Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Paul G. Richardson

Article2019

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Façon, Jae Hoon Lee, Philippe Moreau, Rubén Niesvizky, Meletios A Dimopoulos, Roman Hájek, Luděk Pour, Artur Jurczyszyn, Lugui Qiu, Zandra Klippel, Anita Zahlten‐Kumeli, Muhtarjan Osman, Bruno Paiva, Jesús F. San Miguel